NEW YORK, Sept. 08, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TechnipFMC plc (NYSE:FTI) from April 27, 2017 through July 24, 2017, inclusive (the “Class Period”) of the important October 2, 2017 lead plaintiff deadline. The lawsuit seeks to recover damages for TechnipFMC investors under the federal securities laws.
To join the TechnipFMC class action, go to http://rosenlegal.com/cases-1179.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) TechnipFMC had a material weakness in its internal control over rates used in the calculations of the foreign currency effects on certain of its engineering and construction projects; (2) accordingly, TechnipFMC lacked effective internal controls over financial reporting; and (3) as a result, TechnipFMC’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 2, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1179.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
FDA Approves Mitapivat for Anemia in Thalassemia Patients
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 



